Global Research and Evidence Lab 14 August 2024 First Read Sundrug Q1 FY3/25 results: OP broadly in line with the company's plan Q: How did the results compare vs expectations? A: Q1 FY3/25 OP came in at ¥10.9bn, up 10% yoy, which is a solid result relative to our forecast of ¥10.5bn and the IBES consensus of ¥10.6bn. The company says OP was broadly in line with its plan. By segment, in the drugstore business, sales came in short and OP undershot management's budget slightly, whereas the discount store busi ...